Observation of Treatment With Certolizumab Pegol in Daily Practice (FasT)

UCB

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT01069419

RA0027

Details and patient eligibility

About

This is an observational, non-interventional, non-comparative, post-authorization safety study to evaluate efficacy and long-term safety of Cimzia in adult patients with RA in need of treatment with a biological product.

Full description

The purpose of this study is to assess the clinical efficacy of Cimzia in achieving clinical remission after two years of therapy. The observational nature of the study leaves the therapeutic decision exclusively within the discretion of the treating physician.

Enrollment: 1,117 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients eligible for treatment with Cimzia as defined in EU approved SmPC

Exclusion criteria

• Patient previously treated with Cimzia. Patient with known hypersensitivity to any component of Cimzia

Trial design

1,117 participants in 1 patient group

Cimzia

Description:

All patients will be treated with Cimzia according to normal clinical practice for the prescribing physician and as defined by the SmPC